The Alzheimer's Association today launched a $100 million global clinical trial designed to answer one of the most consequential questions in aging medicine: can combining a GLP-1 receptor agonist drug with a proven lifestyle intervention actually prevent dementia?
The trial — named PROTECT-Cog, which stands for Prevention of Risk fOr cogniTive dEcline through Combined Therapy — was announced for the first time today at the Alzheimer's Association International Conference (AAIC) 2026 in London. The conference, running July 12–15, draws nearly 12,000 researchers and health-care professionals from around the world.
The study is described as a first-of-its-kind global clinical trial designed to evaluate whether combining a proven multidomain lifestyle intervention with a metabolism-targeting drug, such as a GLP-1 agonist, can further reduce the risk of cognitive decline, mild cognitive impairment (MCI), and dementia in at-risk older adults.
No drug has ever been proven to prevent dementia. The PROTECT-Cog Study is designed to find out whether a combination approach — targeting metabolism and lifestyle simultaneously — might accomplish what no single intervention has yet achieved.
Why This Matters
The global case for urgency is immediate. The American Cancer Society and WHO's Global Cancer Statistics 2026 — released earlier this month — documented the scale of the chronic disease burden heading toward 2050. Dementia is part of that trajectory. Approximately 7 million Americans currently live with Alzheimer's disease, and that number is projected to grow to 13 million by 2050 as the population ages.
Existing Alzheimer's drugs — including the recently approved amyloid-targeting antibodies — address the disease after it has already begun. They do not prevent it. The PROTECT-Cog Study represents a different strategy entirely: intervening years before dementia develops, in older adults who are at elevated risk but have not yet developed the disease.
The rationale for testing GLP-1 drugs in this context is growing. A Phase 2b trial of the GLP-1 drug liraglutide, reported at AAIC 2024, found that it may reduce shrinking in parts of the brain that control memory, learning, language and decision-making by nearly 50 percent compared to placebo. That finding, combined with mechanistic studies suggesting GLP-1 agonists play a role in brain inflammation, metabolism, and vascular health, is what motivated the Alzheimer's Association to pair the drug class with its proven lifestyle intervention platform.
What We Know So Far
The PROTECT-Cog Study will enroll older adults who are at increased risk for cognitive decline. The trial has two main arms:
- A structured lifestyle intervention program with intensive coaching and support
- A structured-lite version of the same core program with fewer touchpoints
Both arms of the lifestyle trial will separately assess the impact of adding a metabolism-targeting drug — such as a GLP-1 agonist — to determine which combination offers the greatest cognitive protection.
The lifestyle intervention component is built on the U.S. POINTER study — a two-year, multisite clinical trial that found intensive, structured lifestyle intervention (focused on physical exercise, nutrition, cardiovascular health monitoring, cognitive challenge, and social engagement) improved cognitive function in older adults at risk for decline. The LatAm-FINGERS study, also presented at AAIC 2026, confirmed similar findings across Latin American populations.
The drug component will test GLP-1 agonists or similar metabolism-targeting agents. Other studies suggest GLP-1s are most protective against dementia in patients with obesity or a high BMI, which helps define the population most likely to benefit and informs participant selection criteria.
Additional details — including the specific GLP-1 drug to be tested, enrollment size, site locations, and eligibility criteria — are expected to be released as the trial progresses into the operational phase.
Where Enrollment Will Matter Most
The PROTECT-Cog Study is described as a global trial, meaning enrollment will span multiple countries. Within the United States, sites are expected to be distributed across major academic medical centers, following the model of the U.S. POINTER study, which enrolled participants from diverse backgrounds across multiple cities.
Older adults with risk factors for dementia who are also metabolically eligible for GLP-1 therapy — meaning those with obesity, type 2 diabetes, or related metabolic conditions — may represent the most relevant candidate population based on the existing evidence. Enrollment criteria are expected to be published through the Alzheimer's Association clinical trials finder.
What Doctors and Experts Say
STAT News, covering AAIC 2026 from London, described the PROTECT-Cog announcement as part of a conference mood in which dementia prevention — not just treatment — has become the central focus of the world's largest Alzheimer's research gathering. Researchers at the conference noted that while lifestyle interventions have proven benefits, the question of whether adding a drug amplifies those benefits remains genuinely unanswered.
The Alzheimer's Association's full press release described the trial as building on the success of U.S. POINTER and LatAm-FINGERS studies, representing the next phase in advancing risk reduction and prevention strategies for Alzheimer's and other diseases that cause dementia.
The Phase 2b liraglutide data from AAIC 2024, while promising, have not been confirmed in a Phase 3 trial. PROTECT-Cog is designed to provide the larger, longer-term evidence base needed to establish whether GLP-1 drugs can play a role in dementia prevention.
What the Evidence Shows and What It Does Not
MedicalDaily Evidence Check
- Trial name: PROTECT-Cog Study (Prevention of Risk fOr cogniTive dEcline through Combined Therapy)
- Sponsor: Alzheimer's Association
- Announced: July 13, 2026, at AAIC 2026, London
- Budget: $100 million
- Design: Global clinical trial; two lifestyle intervention arms; add-on assessment of GLP-1 agonist or similar drug
- Primary question: Does combining proven multidomain lifestyle intervention with a GLP-1 agonist reduce cognitive decline, MCI, and dementia in at-risk older adults more than lifestyle intervention alone?
- Supporting precedent: U.S. POINTER (lifestyle intervention improves cognition); Phase 2b liraglutide trial (GLP-1 may slow brain atrophy by ~50% vs. placebo in mild Alzheimer's)
- What this trial does not yet establish: Whether GLP-1 drugs prevent dementia — that is the question the trial is designed to answer. No results are available; the trial launched today.
- FDA approval status for GLP-1s in dementia prevention: None. These drugs are not approved for cognitive indications.
- What readers should know: Do not begin GLP-1 therapy specifically for dementia prevention based on current evidence. Discuss all medications with your clinician.
Who Should Pay Attention to This Research
This trial is most immediately relevant to:
- Older adults with known risk factors for cognitive decline — particularly those with obesity, type 2 diabetes, high blood pressure, or cardiovascular disease — who are also candidates for GLP-1 therapy
- Researchers and clinicians working at the intersection of metabolic health and cognitive aging
- People currently taking GLP-1 medications for diabetes or obesity who have wondered whether the drugs may offer cognitive benefits
- Caregivers and family members of older adults who are monitoring cognitive health and looking for potential preventive strategies
Symptoms and Warning Signs to Watch For
The PROTECT-Cog Study is designed for prevention — it targets people who are at risk for cognitive decline but have not yet been diagnosed with dementia. If you or a family member is noticing early signs of memory or cognitive change, those symptoms warrant evaluation independent of this trial.
Warning signs that should prompt a clinical evaluation include: memory loss that disrupts daily life, increased difficulty planning or problem-solving, confusion about time or place, difficulty completing familiar tasks, changes in mood or personality, and withdrawal from social activities.
The Alzheimer's Association 24/7 helpline at 1-800-272-3900 can provide guidance, care consultation, and clinical trial referrals.
What You Can Do Now
- If you are an older adult with metabolic risk factors for cognitive decline, discuss the PROTECT-Cog Study with your clinician when enrollment opens. Eligibility criteria will be available through the Alzheimer's Association clinical trials finder .
- Do not begin GLP-1 therapy specifically for dementia prevention based on today's announcement. The trial is testing whether that benefit exists — the answer is not yet known.
- The lifestyle intervention component of the trial — structured physical exercise, nutrition, cognitive challenge, social engagement, and cardiovascular monitoring — reflects practices that are already supported by evidence for brain health. These steps are worth pursuing independent of any trial enrollment.
- Follow updates from the Alzheimer's Association and AAIC 2026 press releases as additional trial details are released.
Cost and Access: What Patients Should Know
Clinical trial participation in federally funded or major foundation-sponsored trials such as PROTECT-Cog is typically provided at no cost to participants. Participants usually receive study interventions, assessments, and some travel reimbursement. When enrollment details are released, eligibility criteria, site locations, and participation requirements will be published.
The lifestyle interventions being tested in PROTECT-Cog — exercise, nutrition counseling, cognitive programs, and cardiovascular monitoring — are generally covered by insurance when prescribed for medical purposes. Discuss the components of a brain-health lifestyle program with your primary care physician or geriatrician.
What Happens Next
The Alzheimer's Association will release additional details about PROTECT-Cog — including the specific GLP-1 drug or class of drugs to be tested, enrollment size, site locations, eligibility criteria, and timeline — as the trial moves into operational planning. Results from a trial of this scale typically take five to seven years from launch to primary data readout.
Additional findings from AAIC 2026 — including the LatAm-FINGERS results, the semaglutide observational data, and other prevention research — are being presented through July 15, 2026. MedicalDaily will report on the most clinically significant findings from the conference as they are released.
The Bottom Line
The Alzheimer's Association has launched the largest dementia prevention trial in history — $100 million, global enrollment, testing whether GLP-1 drugs combined with a proven lifestyle intervention can prevent cognitive decline before it begins. The answer is not yet known. This is the trial designed to find out. For the 7 million Americans with Alzheimer's and the tens of millions more at risk, it is one of the most important clinical questions in aging medicine. Today's launch is the beginning of the evidence, not the end.
